Quick Answer
CAPRICOR THERAPEUTICS, INC. reported R&D Expense of $84.45 million for fiscal year 2025.
CAPRICOR THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $84.45M | +69.0% |
| 2024 | $49.97M | +37.1% |
| 2023 | $36.45M | +67.1% |
| 2022 | $21.82M | +60.8% |
| 2021 | $13.57M | +60.5% |
| 2020 | $8.46M | +64.5% |
| 2019 | $5.14M | -57.4% |
| 2018 | $12.07M | +12.1% |
| 2017 | $10.77M | -32.9% |
| 2016 | $16.04M | +16.6% |
| 2015 | $13.76M | +76.7% |
| 2014 | $7.79M | +49.8% |
| 2013 | $5.20M | +97.3% |
| 2012 | $2.63M | -36.3% |
| 2011 | $4.14M | +1.4% |
| 2010 | $4.08M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.36M | +72.4% | -7.7% |
| June 30, 2025 | $22.05M | +76.3% | +16.6% |
| March 31, 2025 | $18.92M | +70.4% | +60.2% |
| September 30, 2024 | $11.81M | +17.7% | -5.6% |
| June 30, 2024 | $12.50M | +41.8% | +12.6% |
| March 31, 2024 | $11.10M | +44.9% | +10.7% |
| September 30, 2023 | $10.03M | +82.2% | +13.7% |
| June 30, 2023 | $8.82M | +77.6% | +15.1% |
- CAPRICOR THERAPEUTICS, INC. showed an increase of +69.0% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, CAPRICOR THERAPEUTICS, INC.’s r&d expense has grown by 1969.5% (from $4.08 million to $84.45 million).
- The most recent figure is from CAPRICOR THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: